TAG:
anatomic pathologist
Pathologist Activities Evolve In VA’s “Paperless” Hospitals
“When a hospital or laboratory goes ‘paperless’, it’s no longer ‘business as usual’ for pathologists.” —Bruce Dunn, M.D. CEO SUMMARY: One outcome of the Veteran Administration’s (VA) ongoing effort to create a totally-integrated i…
Health Line Clinical Labs, ChromaVision, Cytyc, TriPath, Quest Diagnostics
HEALTH LINE CLINICAL LABS SIGNS $10 MILLION FRAUD SETTLEMENT WITH FEDS DESPITE THE EVIDENCE that packing unnecessary tests into test panels is not acceptable to Medicare and Medicaid authorities, some laboratories continue the practice. Health Line Clinical Laboratories, Inc…
Arguing in Favor of Regional Laboratory Networks
TWO STORIES IN THIS ISSUE OF THE DARK REPORT DEMONSTRATE why regional laboratory networks are a business model which should be revisited by hospital laboratories with outreach programs. Seattle provides a great example of how an existing laboratory network gives hospitals in that region an addition…
Welsh Carson Pays $1.14 Billion To Acquire U.S. Oncology, Inc.
EVEN AS THE LAST ISSUE of THE DARK REPORT was reaching clients with news of Genzyme Corp.’s offer to buy IMPATH Inc., another big oncology deal was announced. On March 22, 2004, Welsh, Carson, Anderson & Stowe announced an offer of $15.05 per …
AmeriPath Reports on 2003, Its First Year as a Private Firm
WILL BUSINESS BE BETTER for AmeriPath, Inc. as a private company than it was as a publicly-traded firm? Its 2003 financial report indicates some interesting challenges, many common to all laboratories. First, a look at basic numbers. AmeriPath’s net revenues grew from $478.8 milli…
New Competitors Line Up In Oncology Marketplace
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
Anatomic Path Trends Portend Deep Changes
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
Changing the Way Laboratories Do Business
I HOPE BOTH PATHOLOGISTS AND LABORATORY ADMINISTRATORS pay close attention to our coverage of early-adopter hospital laboratories and how they are using “Lean” quality management methods to boost performance of their laboratories. These labs are harvesting productivity gains in the range of 30% t…
How “Lean” is Benefiting Early-Adopter Laboratories
CEO SUMMARY: First steps toward a radical change in clinical laboratory operations are under way in a handful of early-adopter laboratories. This movement is so new that little information about their successes can be published. But the early evidence is compelling. For those labs willing…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.